- Poster presentation
- Open Access
Quantitative 19F MRI and CT tracking of the microencapsulated stem cells in a rabbit peripheral arterial disease model
© Wang et al.; licensee BioMed Central Ltd. 2014
- Published: 16 January 2014
- Peripheral Arterial Disease
- Isotropic Voxel Size
- TrueFISP Sequence
- Otsu Thresholding
- Microencapsulation Method
Nearly 12% of Americans suffer from peripheral arterial disease (PAD) and many are not eligible for conventional treatment. Transplanting stem cells (SC) in microcapsules impregnated with X-ray/MR-visible contrast agents (XMRCaps) offers a novel means for PAD therapy to avoid immunorejection and enable tracking using non-invasive imaging modalities. Here we explore quantitative serial cell tracking of XMRCaps using conventional c-arm CT and 19F-MRI containing either human or rabbit SCs (XenoSC or alloSC, respectively) in a non-immunosuppressed rabbit PAD model.
XMRCaps were produced using a modified alginate-poly-L-lysine-alginate microencapsulation method impregnating 12% v/v perfluorooctyl bromine (PFOB) and XenoSC or AlloSC. In vitro validations were performed in an agarose phantom consisting of four layers of 50, 100, and 200 XMRCaps. C-arm CT images (dynaCT, Siemens Artis Zee) were acquired and reconstructed at 0.46 mm isotropic voxel size. 19F 3T MRI was acquired with a 4-channel Tx/Rx 19F coil using a 3D TrueFISP sequence (Siemens Tim Trio, 4.1 ms TR; 2.0 ms TE; 70° FA; 1.3 mm isotropic voxel size; 32 averages). Reference 1H MRI was acquired with the system body or body matrix coil using a 3D gradient echo sequence. In vivo c-arm CT and MRI studies were performed at same day, one and two weeks after an intramuscular injection of 3 ml of XMRCaps in the hindlimb (n = 10) using identical imaging parameters as the in vitro studies (voxel size 1.5 × 1.5 × 2 mm). To test the repeatability of 19F MRI, the imaging sets were acquired twice on the same day in one rabbit with the coil repositioned in between. Reference markers with known PFOB concentrations were placed within the imaging field at the same depth of the injections relative to the coil to enable field inhomogeneity correction. Segmentation of the injection sites in the c-arm CTs and 19F MRIs was performed with the Otsu thresholding algorithm. Concentration was then determined by averaging the integrated 19F signal intensity over the segmented volume after normalization to standards.
MRI provides accurate assessment of XMRCap volumes, which were slightly larger than CT due to partial volume effects with the larger MRI voxel size. In vivo XMRCaps injection site volumes could be assessed on MRI and CT. However, only MRI was able to quantify the XMRCaps 19F concentration. Result shows that XMRCaps serial alternations with XenoSC and AlloSC are not significantly different, which demonstrates that XMRCaps prevent the immunorejection of the mismatched SCs.
Siemens AG, NIH R33-HL089029, and the Maryland Stem Cell Research Foundation (2008-MDSCRFII-0399/2011-MDSCRFII-0043).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.